Home > Boards > US Listed > Medical - Healthcare > Gilead Sciences, Inc. (GILD)

Seeing some consolidation. Wouldn't be surprised if around

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
fung_derf Member Profile
Member Level 
Followed By 222
Posts 110,508
Boards Moderated 23
Alias Born 08/30/01
160x600 placeholder
Gilead's Magrolimab Gets FDA Breakthrough Therapy Designation in Myelodysplastic Syndrome Dow Jones News - 9/15/2020 8:54:00 AM
Gilead’s Magrolimab, an Investigational Anti-CD47 Monoclonal Antibody, Receives FDA Breakthrough Therapy Designation for Tr... Business Wire - 9/15/2020 8:00:00 AM
Hospitalized Covid-19 Patients Recovered Faster With Arthritis Drug Dow Jones News - 9/14/2020 11:26:00 AM
Immunomedics Shares More Than Double After Gilead Deal Dow Jones News - 9/14/2020 8:26:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/14/2020 8:02:48 AM
Gilead Acquires Cancer-Drug Maker -- WSJ Dow Jones News - 9/14/2020 3:02:00 AM
Gilead Reaches Deal to Buy Immunomedics for $21 Billion -- 5th Update Dow Jones News - 9/13/2020 9:01:00 PM
Gilead Reaches Deal to Buy Immunomedics for $21 Billion--4th Update Dow Jones News - 9/13/2020 4:29:00 PM
Gilead Sciences to Acquire Immunomedics Business Wire - 9/13/2020 3:00:00 PM
Gilead Nears Deal to Buy Immunomedics for More Than $20 Billion--3rd Update Dow Jones News - 9/12/2020 4:01:00 PM
Gilead Nears Deal to Buy Immunomedics for More Than $20 Billion--2nd Update Dow Jones News - 9/12/2020 3:50:00 PM
Gilead Nears Deal to Buy Immunomedics for More Than $20 Billion--Update Dow Jones News - 9/12/2020 3:39:00 PM
Gilead Nears Deal to Buy Immunomedics for More Than $20 Billion Dow Jones News - 9/12/2020 3:22:00 PM
Kite Submits Supplemental Biologics License Application to U.S. Food & Drug Administration for Yescarta® in Relapsed or Refr... Business Wire - 9/4/2020 8:30:00 AM
Gilead's Kite Forms AML Collaboration With HiFiBiO Therapeutics Dow Jones News - 9/3/2020 8:56:00 AM
Kite and HiFiBiO Therapeutics Partner to Discover Novel Targets and Antibodies Against Acute Myeloid Leukemia Business Wire - 9/3/2020 8:00:00 AM
Jounce Therapeutics Shares Up 54% After License Agreement With Gilead Dow Jones News - 9/1/2020 10:21:00 AM
Gilead, Jounce In License Agreement for Immunotherapy Program Dow Jones News - 9/1/2020 9:19:00 AM
Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program GlobeNewswire Inc. - 9/1/2020 8:30:10 AM
Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program Business Wire - 9/1/2020 8:30:00 AM
Gilead Says Veklury Gets EUA From FDA to Treat Patients With Moderate Covid-19 Dow Jones News - 8/28/2020 5:42:00 PM
Gilead’s Investigational Antiviral Veklury® (Remdesivir) Receives U.S. Food & Drug Administration Emergency Use Authorizat... Business Wire - 8/28/2020 4:45:00 PM
Gilead Announces Presentation of More Than 40 Abstracts From Extensive Liver Disease Programs at the Digital International Li... Business Wire - 8/25/2020 2:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/19/2020 12:53:49 PM
Galapagos, Gilead Shares Fall as FDA Seeks More Filgotinib Data Dow Jones News - 8/19/2020 8:24:00 AM
fung_derf Member Level  Monday, 06/01/20 10:42:54 AM
Re: None
Post # of 4372 
Seeing some consolidation. Wouldn't be surprised if around $72.45 is near the bottom for the week. Also wouldn't be surprised to see above $79 for the weekly high.
Below $70.70 would be a negative indicator. $81 would be a positive one.
Writing puts at 67.5 seem like a solid strategy to me at the moment and that's about it.

Buy on the way up!!! Just my opinion, of course.
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences